Mylan CEO Heather Bresch, facing bipartisan criticism over the pricing of EpiPen, told the House Oversight and Government Reform Committee Wednesday (Sept. 21) the company only nets a profit of approximately $100 per two-unit pack of EpiPen. The embattled CEO also laid out Mylan's plans to submit a new reformulation of EpiPen to FDA within days of the hearing, saying the company hoped to extend the shelf life of the drug from 18 months to 24 months or longer. The...